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A	 therapeutic	 solution	 to	 the	 current	 corona-
virus	 (COVID-19)	pandemic	 is	 urgently	needed,	
but	 new	 drug	 discovery	 and	 development	 is	 a	
lengthy	 process.	 Pharmaceuticals	 derived	 from	
plants	 and	 fungi	 remain	 important	 in	 our	 ar-
mory	 against	 numerous	 diseases	 (1,	 2),	 yet	
much	 of	 plant	 and	 fungal	 biodiversity	 remains	
unexplored	 for	 drug	 discovery	 (3).	 Of	 about	
390,000	known	plant	 species,	7%	have	medici-
nal	 uses	 (4),	 and	 the	 wider	 potential	 of	 the	
world’s	 flora	 to	 yield	 new	medicines	 has	 been	
discussed	by	conservation	biologists	for	decades	
(5).	We	 urgently	 need	 a	 comprehensive	 scien-




specimens	 already	 housed	 in	 herbaria,	 botanic	
gardens	(6),	and	fungal	biological	resource	cen-
ters.	Herbaria	host	about	380	million	specimens	
from	 all	 described	 plant	 species,	 and	 botanic	
gardens	maintain	about	one-third	of	all	known	
land	 plant	 species	 (7).	 Fungal	 collections	 cur-
rently	host	about	860,000	strains	worldwide	(8).	
These	 collections	 are	 invaluable	 resources	 rep-
resenting	unparalleled	chemical	diversity.		
Evolutionary	 relationships	 inferred	 from	
DNA	could	be	used	to	guide	selection	of	species	
with	medicinal	 potential.	 Just	 a	 few	milligrams	
from	 specimens	 enable	 comprehensive	 chemi-












tion	 of	 therapeutic	 candidates	 from	 nature	
could	 help	 humanity	 prepare	 for	 future	 health	
challenges.	 Scientists,	 stakeholders	 and	 gov-
ernments	must	establish	functional	and	equita-
ble	 agreements	 to	 ensure	 that	 this	work	 com-
plies	 with	 the	 Nagoya	 Protocol,	 Access	 and	
Benefit	Sharing	legislation	and	reflects	the	value	
and	 origins	 of	 specimens	 collected	 during	 the	
colonial	 era	 (11).	 It	 is	 also	 critical	 that	benefits	
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